Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CEST
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 MERCK AND : LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovar..
08/17 ANOTHER VIEW : Merck CEO shows the power of corporate conscience
08/17 Chinas HitGen bags new drug discovery deal with Aduro
08/17 CHARLOTTESVILLE VIOLENCE : Amid stream of resignations, Trump disbands Manufactu..
08/16 MERCK AND : Fourth CEO resigns from Trump's American Manufacturing Council
08/15DJWal-Mart CEO Criticizes Trump's Virginia Response
08/15DJMore Corporate Executives Quit Trump Advisory Council
08/15 Three CEOs resign from Trump's American Manufacturing Council
08/15DJKENNETH FRAZIER : Three CEOs Quit Trump Council -- WSJ
More news
News from SeekingAlpha
08/17 My Chemical Romance
08/17 BOEING : Money Over Morals
08/16 Bristol-Myers Squibb Combination Treatment Not At The End Of The Crossroad
08/15 BRISTOL-MYERS SQUIBB : HIV Franchise Was Never A Big Part Of The Game Plan
08/15 WALL STREET BREAKFAST : More CEOs Resign From Trump Council
Financials ($)
Sales 2017 40 292 M
EBIT 2017 13 703 M
Net income 2017 5 621 M
Debt 2017 4 312 M
Yield 2017 3,00%
P/E ratio 2017 29,54
P/E ratio 2018 18,67
EV / Sales 2017 4,35x
EV / Sales 2018 4,21x
Capitalization 171 005 M
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY6.51%171 005
JOHNSON & JOHNSON15.77%360 112
NOVARTIS10.12%220 515
ROCHE HOLDING LTD.5.33%218 264
PFIZER2.71%198 663
SANOFI7.39%122 810